CVS Health (CVS) said, for 2025, it increased adjusted EPS guidance range to $6.60 to $6.70 from $6.55 to $6.65. The company raised adjusted operating income guidance range to $14.22 billion to $14.39 billion from $14.14 billion to $14.31 billion. Also, total revenues guidance was raised to at least $400.0 billion from at least $397.3 billion. GAAP loss per share is now projected in a range of $0.32 to $0.22, revised from previous guidance of a loss of $0.34 to $0.24.
The company initiated its 2026 full-year financial guidance with: total revenues of at least $400.0 billion; adjusted operating income guidance range of $15.07 billion to $15.41 billion; GAAP EPS guidance range of $5.94 to $6.14; and adjusted EPS guidance range of $7.00 to $7.20.
CVS Health expects to achieve a mid-teens adjusted EPS CAGR through 2028.
CVS Health also announced the launch of a new technology products and services offering, focusing on Engagement as a Service.
Shares of CVS are up 3% to $79.00 in pre-market trade on Tuesday.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.